Pregnancy registry for women with chronic neurological conditions
Official title: Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA): Pregnancy Registry for Women With Chronic Conditions
Run by University of California, San Francisco · NCT06940323 · Data updated 2026-11-12
This study is collecting information and samples from pregnant women with chronic neurological conditions to see how pregnancy affects their health and their baby's development.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 64 Years |
| Sex | Women only |
| Enrollment | 250 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | March 21, 2017 |
| Main results expected | June 2030 |
| Study ends | June 2035 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT06940323 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include pregnant women or those contemplating pregnancy who have a diagnosis of multiple sclerosis, clinically isolated syndrome, neuromyelitis optica spectrum disorder, or other specified chronic conditions.
✕Probably not a fit
Patients who are unwilling to provide informed consent or do not have a chronic condition may not receive any benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PRISMA is an observational pregnancy registry that collects comprehensive information about pregnancy in women with chronic neurological conditions such as multiple sclerosis, clinically isolated syndrome, neuromyelitis optica spectrum disorder, and myasthenia gravis. Participants will provide biosamples, including blood, breast milk, and stool samples, at specific time points, along with completing online surveys. The study aims to develop a repository of samples to gain insights into the relationship between pregnancy, neurological conditions, and maternal and infant health. This includes monitoring maternal outcomes and infant development over time.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pregnancy outcomes in women with chronic neurological conditions, potentially leading to improved maternal and infant health strategies.
How similar studies have gone: While there have been studies focusing on pregnancy outcomes in chronic conditions, this specific approach of creating a comprehensive pregnancy registry with biosample collection is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant or contemplating pregnancy * Female, aged 18 to 64 years * Diagnosis of one of the following conditions: * Clinically Isolated Syndrome (CIS) or Multiple Sclerosis (MS), based on the 2010 McDonald Criteria * Neuromyelitis Optica Spectrum Disorder (NMOSD) * Inflammatory Bowel Disease (IBD) * Rheumatoid Arthritis (RA) * Myasthenia Gravis * Lupus * Other chronic neurological conditions * Willing to provide biosamples and/or complete surveys at specified timepoints * Women without a chronic condition who are pregnant or contemplating pregnancy (as part of the control group) Exclusion Criteria: \- Unwillingness to provide informed consent
Where it's running
-
University of California-San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Riley Bove, MD, MSc — University of California, San Francisco
- Study coordinator: Min Ji Kim Kim, BA
- Email: minji.kim3@ucsf.edu
- Phone: 415-502-7209
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pregnant Women with Neuroimmune Diseases: A long-term follow-up study
This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.
-
KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases
This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.
-
Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases
This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.
-
Identifying biomarkers for autoimmune diseases affecting the nervous system
This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.
-
Using optic nerve imaging to predict progression after a first demyelinating episode
This trial will try a dedicated optic nerve MRI in people who recently had a first demyelinating event (clinically isolated syndrome) to see if optic nerve involvement predicts who will have a second relapse and be diagnosed with multiple sclerosis.
-
AI-assisted care for Multiple Sclerosis
This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.